Uveal Diseases: Clinical Trials

1,157 trials for Uveal Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

604 completed, 180 unknown, 116 recruiting, 107 terminated. 317 Phase 2, 188 Phase 1, 170 Not applicable, 144 Phase 3, 81 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 2317Completed 168, Terminated 44, Unknown 29, Recruiting 28, Active not recruiting 22, Withdrawn 19, Not yet recruiting 4, Enrolling by invitation 2, Suspended 1
Phase 1188Completed 98, Terminated 27, Recruiting 22, Unknown 14, Active not recruiting 13, Withdrawn 7, Enrolling by invitation 3, Not yet recruiting 3, Suspended 1
Not applicable170Completed 83, Unknown 38, Recruiting 23, Terminated 10, Active not recruiting 6, Withdrawn 6, Not yet recruiting 3, Enrolling by invitation 1
Phase 3144Completed 79, Terminated 24, Unknown 15, Recruiting 14, Active not recruiting 7, Withdrawn 4, Not yet recruiting 1
Phase 481Completed 42, Unknown 16, Not yet recruiting 9, Terminated 5, Withdrawn 4, Recruiting 3, Active not recruiting 2
Early Phase 16Completed 2, Terminated 2, Unknown 1, Withdrawn 1

Follow Uveal Diseases: new trials by email Literature Review of Uveal Diseases trials Research Report on Uveal Diseases

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases
Autologous Tumor Infiltrating Lymphocytes, Melphalan, Interleukin-2 - Uveal Melanoma, Metastatic Cutaneous Melanoma
Phase 1Not yet recruitingVastra Gotaland Region62027-01-312026-09-09
Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma
Autologous Tumor Infiltrating Lymphocytes (TIL), Melphalan, Interleukin-2 - Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma
Phase 1Not yet recruitingVastra Gotaland Region182027-01-012026-09-09
Pneumatic Displacement With Anti-VEGF and Concomitant rtPA for PCV-related Submacular Hemorrhage
Anti-VEGF agents, tissue plasminogen activator (rtPA), Pneumatic displacement with intravitreal gas - Polypoidal Choroidal Vasculopathy (PCV), Submacular Hemorrhage
Phase 4Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine802027-01-012026-11-17
Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial
aflibercept 8 mg - Polypoidal Choroidal Vasculopathy, Polypoidal Choroidal Vasculopathy (PCV)
Phase 3RecruitingYeungnam University College of Medicine502026-12-242026-02-05
Morpho-functional Evaluation of the Retina and Choroid Using Multimodal Imaging in Healthy Subjects and Patients With Retino-choroidal Diseases
Retinal Diseases, Choroidal Diseases
Not yet recruitingFondazione G.B. Bietti, IRCCS1252026-12-012026-11-12
Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research
Pericarditis, Tako-TSUBO Cardiomyopathy
Not yet recruitingAssistance Publique - Hôpitaux de Paris3002026-12-012026-11-13
Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis
Blood sample, Adalimumab Injection - Uveitis, Chronic Disease
Phase 4Not yet recruitingCentre Hospitalier Universitaire de Saint Etienne3202026-12-012026-11-19
Gryrotonic Training in Behcet-diseased Elders With Breast Cancer
exercise - Breast Cancer, Behcet Disease
Not applicableRecruitingCairo University402026-11-302026-11-10
Collection and Storage of Biological Samples From Patients Affected by Uveitis for Immunological and Multi-omic Studies
Uveitis
Not yet recruitingIRCCS Ospedale San Raffaele2002026-11-302026-11-16
Efficacy and Safety of Adalimumab for the Treatment of Ocular Inflammation
Adalimumab PFS and Pen - Non-infectious Anterior Uveitis, Non-infectious Intermediate Uveitis
Not applicableNot yet recruitingSamsung Medical Center402026-11-152026-11-09
A Clinical Trial Of Tulisokibart In Participants With Active, Non-Infectious Uveitis (MK-7240-019)
Tulisokibart, Placebo, Background prednisone therapy - Noninfectious Intermediate, Posterior, or Panuveitis
Phase 2RecruitingMerck Sharp & Dohme LLC872026-11-042026-11-16
Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II
Valganciclovir, Ganciclovir (GCV), Placebo - Cytomegalovirus (CMV), Anterior Uveitis
Phase 2Not yet recruitingUniversity of California, San Francisco1172026-11-012026-08-11
A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration
VIS-101 6.0mg Low concentration, VIS-101 6.0mg High concentration, VIS-101 9.0mg High concentration - Neovascular Age Related Macular Degeneration(nAMD)
Phase 2Not yet recruitingEverest Medicines (China) Co.,Ltd.2442026-11-012026-11-05
Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp
Dexamethasone - Uveal Melanoma, Metastatic
Phase 2WithdrawnUniversity of California, San Diego2026-11-012026-11-06
Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors
REGN13089-M404-M2980 - Advanced Solid Tumors
Phase 1 / Phase 2RecruitingRegeneron Pharmaceuticals3202026-10-282026-11-18
Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma
RBP-01 - Uveal Melanoma
Phase 1 / Phase 2Not yet recruitingReBio Pharma302026-10-012026-08-05
Clinical, Laboratory, and Therapeutic Analysis of Behçet's Disease in Assiut
Behçet's Disease
Not yet recruitingAssiut University302026-09-302025-09-05
Serum EBI-3 Protein Levels in Behçet's Disease
Behçet Disease
Not yet recruitingAssiut University902026-09-262026-09-28
Topical Insulin for Glaucoma (TING2)
EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month) - Open Angle Glaucoma, Primary Open Angle Glaucoma
Phase 1 / Phase 2Enrolling by invitationStanford University902026-09-102026-10-13
PANDA-ASOCT: Paediatric Anterior Uveitis Detection With Automated Image Analysis Using ASOCT
Slit Lamp Examination, Anterior segment ocular coherence tomography (ASOCT) - Uveitis
RecruitingSheffield Children's NHS Foundation Trust3002026-09-092026-09-15

Showing 20 of 1157. Sign in to see all of them.

Narrower conditions

Uveal Melanoma (280)  ·  Uveitis (269)  ·  Choroidal Neovascularization (203)  ·  Macular Degeneration (148)  ·  Behcet Syndrome (132)  ·  Melanoma (125)  ·  Exfoliation Syndrome (72)  ·  Uveitis, Posterior (60)  ·  Uveitis, Intermediate (56)  ·  Macular Edema (54)  ·  Polypoidal Choroidal Vasculopathy (51)  ·  Uveitis, Anterior (48)  ·  Glaucoma, Open-Angle (40)  ·  Panuveitis (38)  ·  Choroideremia (34)

Broader conditions

Eye Diseases (1138)  ·  Pathological Conditions, Signs and Symptoms (357)  ·  Pathologic Processes (338)  ·  Choroid Diseases (327)  ·  Neoplasms by Site (293)  ·  Neoplasms by Histologic Type (292)  ·  Skin and Connective Tissue Diseases (289)  ·  Neoplasms, Nerve Tissue (283)  ·  Neuroectodermal Tumors (283)  ·  Neoplasms, Germ Cell and Embryonal (282)  ·  Nevi and Melanomas (282)  ·  Neuroendocrine Tumors (280)  ·  Skin Diseases (279)  ·  Uveal Neoplasms (278)

Interventions

Ranibizumab (78)  ·  aflibercept (37)  ·  Ipilimumab (30)  ·  Adalimumab (26)  ·  Bevacizumab (26)  ·  Nivolumab (24)  ·  Verteporfin (20)  ·  Triamcinolone Acetonide (18)  ·  Blood Specimen Collection (15)  ·  Cyclophosphamide (15)  ·  Dexamethasone (15)  ·  Methotrexate (15)  ·  pembrolizumab (14)  ·  Interleukin-2 (11)  ·  salicylhydroxamic acid (11)

Sponsors

National Eye Institute (NEI) (58)  ·  Novartis Pharmaceuticals (36)  ·  Assiut University (31)  ·  National Cancer Institute (NCI) (22)  ·  Assistance Publique - Hôpitaux de Paris (17)  ·  Medical University of Vienna (15)  ·  Institut Curie (13)  ·  Memorial Sloan Kettering Cancer Center (11)  ·  Vastra Gotaland Region (11)  ·  Benha University (10)  ·  Novartis (10)  ·  Oregon Health and Science University (10)  ·  M.D. Anderson Cancer Center (9)  ·  Peking Union Medical College Hospital (9)  ·  Sun Yat-sen University (9)

Countries

United States (508)  ·  France (120)  ·  Germany (92)  ·  United Kingdom (91)  ·  Spain (69)  ·  China (68)  ·  Italy (67)  ·  Canada (62)  ·  Australia (55)  ·  Turkey (Türkiye) (52)  ·  Austria (44)  ·  Egypt (38)  ·  Israel (38)  ·  Switzerland (38)  ·  South Korea (37)

Top investigators

Hatice N Sen, M.D. (8)  ·  Quan D Nguyen, MD, MSc (6)  ·  Jeffrey S. Weber, MD, PhD (5)  ·  Nisha Acharya, MD MS (5)  ·  Fereydoun Davatchi, MD (4)  ·  Peter A. Merkel, MD, MPH (4)  ·  Thomas Ciulla, MD (4)

Results publications

PMID 30957581, PMID 37172782, PMID 23290985, PMID 30194931, PMID 30986442, PMID 36787524, PMID 19248087, PMID 19726427, PMID 20498207, PMID 21622969, PMID 21885496, PMID 22426346, PMID 23084240, PMID 24113783, PMID 25667295, PMID 28426849, PMID 28445659, PMID 29528792, PMID 32374423, PMID 33207259, PMID 34968756, PMID 36399237, PMID 36912792, PMID 37316690, PMID 37343623, PMID 38925285, PMID 39033924, PMID 11071039, PMID 11152054, PMID 11153967, PMID 11297486, PMID 11459787, PMID 11468137, PMID 11642370, PMID 11741106, PMID 12039921, PMID 12095806, PMID 12441176, PMID 12459649, PMID 12637048, PMID 12684398, PMID 12707595, PMID 12826605, PMID 12947072, PMID 12967792, PMID 14078870, PMID 14078872, PMID 14557174, PMID 15013874, PMID 15079763

NIH funding

2009 (13), 2019 (8), 2014 (5), 2023 (5), P30CA008748 (4), 2025 (3), N01CM00039 (3), 2008 (2), 2015 (2), 2016 (2), 2017 (2), N01CM00100 (2), N01CM62203 (2), N01CM62206 (2), P30CA006973 (2)